Evaluating Fatty Acid Amide Hydrolase as a Suitable Target for Sleep Promotion in a Transgenic TauP301S Mouse Model of Neurodegeneration
Public Deposited- Creator
-
Martin, Shenée C.
- Affiliation: School of Medicine, Department of Cell Biology and Physiology
-
Joyce, Kathryn K.
- Affiliation: School of Medicine, Department of Cell Biology and Physiology
-
Harper, Kathryn M.
- Affiliation: School of Medicine, Department of Psychiatry
-
Harp, Samuel J.
- Affiliation: School of Medicine, Department of Psychiatry
-
Cohen, Todd J.
- Affiliation: School of Medicine, Department of Neurology
-
Moy, Sheryl S.
- Affiliation: School of Medicine, Department of Psychiatry
-
Diering, Graham H.
- Affiliation: School of Medicine, Department of Cell Biology and Physiology
- Abstract
- Sleep disruption is an expected component of aging and neurodegenerative conditions, including Alzheimer’s disease (AD). Sleep disruption has been demonstrated as a driver of AD pathology and cognitive decline. Therefore, treatments designed to maintain sleep may be effective in slowing or halting AD progression. However, commonly used sleep aid medications are associated with an increased risk of AD, highlighting the need for sleep aids with novel mechanisms of action. The endocannabinoid system holds promise as a potentially effective and novel sleep-enhancing target. By using pharmacology and genetic knockout strategies, we evaluated fatty acid amide hydrolase (FAAH) as a therapeutic target to improve sleep and halt disease progression in a transgenic Tau P301S (PS19) model of Tauopathy and AD. We have recently shown that PS19 mice exhibit sleep disruption in the form of dark phase hyperarousal as an early symptom that precedes robust Tau pathology and cognitive decline. Acute FAAH inhibition with PF3845 resulted in immediate improvements in sleep behaviors in male and female PS19 mice, supporting FAAH as a potentially suitable sleep-promoting target. Moreover, sustained drug dosing for 5–10 days resulted in maintained improvements in sleep. To evaluate the effect of chronic FAAH inhibition as a possible therapeutic strategy, we generated FAAH−/− PS19 mice models. Counter to our expectations, FAAH knockout did not protect PS19 mice from progressive sleep loss, neuroinflammation, or cognitive decline. Our results provide support for FAAH as a novel target for sleep-promoting therapies but further indicate that the complete loss of FAAH activity may be detrimental.
- Date of publication
- 2024
- Keyword
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- License
- Attribution 4.0 International
- Journal title
- Pharmaceuticals
- Journal volume
- 17
- Journal issue
- 3
- Page start
- 319
- Language
- English
- Version
- Publisher
- ISSN
- 1424-8247
- Publisher
- MDPI
Relations
- Parents:
- In Collection:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
pharmaceuticals-17-00319.pdf | 2024-03-04 | Public | Download |